KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBT Margin (2016 - 2026)

Gilead Sciences filings provide 17 years of EBT Margin readings, the most recent being 26.22% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 241.0% to 26.22% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.27%, a 3087.0% increase, with the full-year FY2025 number at 33.27%, up 3087.0% from a year prior.
  • EBT Margin hit 26.22% in Q4 2025 for Gilead Sciences, down from 46.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 46.87% in Q3 2025 to a low of 67.1% in Q1 2024.
  • Median EBT Margin over the past 5 years was 26.85% (2022), compared with a mean of 22.07%.
  • Biggest five-year swings in EBT Margin: tumbled -8756bps in 2024 and later skyrocketed 9183bps in 2025.
  • Gilead Sciences' EBT Margin stood at 10.48% in 2021, then surged by 162bps to 27.49% in 2022, then dropped by -15bps to 23.24% in 2023, then grew by 23bps to 28.63% in 2024, then fell by -8bps to 26.22% in 2025.
  • The last three reported values for EBT Margin were 26.22% (Q4 2025), 46.87% (Q3 2025), and 34.3% (Q2 2025) per Business Quant data.